2018 annual dialysis data report of the JSDT Renal Data Registry: patients with hepatitis

Abstract According to the annual survey of Japanese Society for Dialysis Therapy Renal Data Registry (JRDR) conducted at end 2018, a total 339,841 patients were receiving dialysis (hereinafter, patients) in Japan. This included an investigation individual test results hepatitis B surface antigen (HBsAg), C virus (HCV) antibody (HCV-Ab), HCV-RNA, and serum alanine aminotransferase (ALT) (glutamic pyruvic transaminase [GPT]). The revealed that among Japan, prevalence HBsAg positivity was 1.38% HCV-Ab 4.7% both which markedly lower than corresponding rates documented 2007 (9.8% 4.7%, respectively). proportion HCV-RNA-positive all HCV-Ab-positive 37.5%, also percentage recorded (64.0%). tended increase as vintage increased. not correlated with during first 30 years dialysis; however, it increased beyond 30th year. Trial registration University hospital Medical Information Network (UMIN) Clinical Trials Registry, UMIN000018641 . JRDR approved by ethics committee JSDT (approval number 1-3) registered on August 8, 2015 (accessed June 2, 2020).